# Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

> **NCT07399171** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Halia Therapeutics, Inc.** · enrollment: 112 (estimated)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** HT-4253
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07399171
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-03
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399171, "Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07399171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*